CONRAY 280
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
24-03-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
IOTALAMATE MEGLUMINE
Available from:
Covidien (UK) Commerical Limited
Dosage:
14/50
Pharmaceutical form:
Solution for Injection
Authorization date:
2012-01-06
Summary of Product characteristics
License
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
Conray 280 mg/ml Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
The solution for injection contains meglumine iotalamate 60% w/v (formed in situ by reaction of iotalamic acid and
meglumine) equivalent to organically bound iodine: 280 mg per ml.
Concentration of iotalamic acid: 0.74 millimole/ml.
Each 50ml bottle contains the equivalent of 14g organically bound iodine.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection
Colourless to pale yellow aqueous solution.
4 CLINICAL PARTICULARS
4.1 Therapeutic Indications
This medicinal product is for diagnostic use only.
X-ray contrast medium used for the opacification of vascular and renal systems and female genital tract.
4.2 Posology and method of administration
Route of administration: By intravenous, intra-uterine or intra-arterial injection or injection directly into the chamber of
the heart, depending on the procedure.
Recommended Dosage:
Intravenous Urography
Adults: 40 to 80 ml.
In the absence of preliminary dehydration 40 to 100ml may be used.
Infants and children:
Under 12kg:
2ml/kg body weight.
Over 12kg:
1.5ml/kg. Minimum of 24 ml.
Over 10 years of age:
Read the complete document
